PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine proudly announces today that Foundation Medicine, Inc. (FMI), Cambridge, MA, joins WIN Consortium and becomes a member of the Consortium. The organizations' collaborative research strategy will be presented at the WIN2012 Symposium in Paris, France, on 28-29 June.
WIN Consortium, is a network of 22 academic institutions and industries across the globe, initiated by Cancer Institute Gustave Roussy (IGR), France and University of Texas MD Anderson Cancer Center, USA (MDACC), focusing on biomarker-driven therapeutic clinical trials conducted worldwide.
"The membership of Foundation Medicine, a CLIA certified laboratory using a next generation sequencing platform (NGS), is an opportunity for WIN to access their extensive screening test for aberrations in genes known to be associated with human cancer. WIN Consortium is sponsoring a unique clinical trial matching the genetics of patients' tumors and their responses to targeted therapies, to enable treatment with the therapies most likely to be effective against each individual patient's cancer. Foundation Medicine's participation will be a key strategic feature of WIN Consortium's innovative trial, conducted by Drs. Jean Charles Soria (IGR, France), Razelle Kurzrock (MDACC, USA), Josep Tabernero (VHIO, Spain) and Raanan Berger, (CSMC, Israel)," said Dr. John Mendelsohn, chairman of WIN Consortium.
"Foundation Medicine's industry and academic partnership through this international network complements the company's core cancer diagnostics capability, a fully informative genomic profile that provides physicians with clinically relevant molecular information designed to assist Oncologists in the selection of therapies for their patients and that to match patients with clinical trials specific for their tumor," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. "The clinical trial to be announced during WIN2012, represents an important opportunity to use cutting edge NGS technology in an international setting for treatment decisions and we are proud to be supporting WIN Consortium with our platform."
"To hear more about the collaborative efforts of Foundation Medicine and WIN Consortium, join the WIN2012 Symposium in Paris on 28-29 June, a unique scientific event dedicated to the efficacy of personalized cancer therapeutics. Participants include outstanding investigators from academic institutions and industry - in an open exchange format. The WIN2012 scientific program received the endorsements of ASCO, ESMO, UICC and INCa (*). The WIN Symposium is a unique forum and networking opportunity. Plan your travel and register now as June is a busy period in Paris," said Vladimir Lazar, Chief operating officer of WIN Consortium.
Online abstract submission deadline is May 1st. Abstract will be published in a prestigious international journal, referenced on Pub Med. Early registration closed on April 1st.
About Foundation Medicine
Foundation Medicine is dedicated to improving cancer care through the development of comprehensive NGS cancer diagnostics that identify and interpret an ever-growing set of actionable genomic alterations. Founding advisors are world leaders in genome technology, cancer biology and medical oncology. Please visit the company's website at www.foundationmedicine.com.
Disclaimers:
(*) This program has the ASCO, ESMO, UICC and INCa approval for quality of educational content. The endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgment.
(*)ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50217528&lang=en